Clinical Research Directory
Browse clinical research sites, groups, and studies.
Efficacy and Safety of ALSS Treatment for ICIs-LF in Patients With HCC
Sponsor: Third Affiliated Hospital, Sun Yat-Sen University
Summary
This study aims to investigate the efficacy and safety of artificial liver support system treatment for immune checkpoint inhibitors related liver failure in patients with hepatocellular carcinoma.
Official title: Efficacy and Safety of Artificial Liver Support System Treatment for Immune Checkpoint Inhibitors Related Liver Failure in Patients With Hepatocellular Carcinoma
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2022-08-12
Completion Date
2024-12-31
Last Updated
2024-11-29
Healthy Volunteers
No
Interventions
DPMAS+LPE
Patients will receive treatment of double plasma molecular adsorption system (DPMAS) and low volume plasma exchange (LPE) for three times in two weeks. The volume of plasma adsorption in DPMAS is 5000\~6000 millilitre. The volume of fresh frozen plasma used in LPE is 1000 millilitre.
PE
Patients will receive treatment of plasma exchange (PE) for three times in two weeks. The volume of fresh frozen plasma used in PE is 2000 millilitre.
Comprehensive internal medical treatment
Patients will receive comprehensive internal medical treatment.
Locations (1)
Third Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, China